Mosaic ImmunoEngineering, Inc. reported a net loss of $175,351 for the three months ended March 31, 2026, a slight improvement compared to a net loss of $181,320 during the same period in 2025. The company's total operating expenses decreased to $154,802 from $174,774 year-over-year, primarily due to reduced general and administrative costs. Research and development expenses remained relatively stable, totaling $15,880, compared to $15,803 in the prior year. The basic and diluted loss per common share was $0.02, an improvement from $0.03 in the previous year.
The company’s financial position showed a significant decline in cash and cash equivalents, which fell to $72 from $3,622 at the end of the previous fiscal year. Total current assets decreased to $9,828 from $19,882, while total liabilities increased to $7,661,199 from $7,495,902. The accumulated deficit also widened to $9,701,517 from $9,526,166, reflecting ongoing operational challenges and the need for additional capital to sustain operations.
Mosaic ImmunoEngineering is actively pursuing strategic partnerships and financing opportunities to support its development programs. The company has entered into a Binding Term Sheet with Oncotelic Therapeutics, Inc. to acquire rights to certain cancer therapies and AI technologies, contingent upon securing shareholder approval and waivers from convertible noteholders. This potential acquisition is part of the company's strategy to expand its product pipeline and enhance its market position.
Operationally, the company has not generated any revenue and continues to rely on external funding to support its activities. As of March 31, 2026, Mosaic had no active customer base or user statistics to report, and its employee headcount remains unchanged. The company is focused on advancing its lead clinical candidate, MIE-101, while managing its limited resources. The management has expressed concerns regarding its ability to continue as a going concern, emphasizing the critical need for capital to fund future operations.
Looking ahead, Mosaic ImmunoEngineering anticipates that its cash on hand will not meet operational and capital requirements for the next twelve months. The company is exploring various financing options, including equity and debt offerings, but acknowledges the challenges posed by current market conditions. The management's outlook remains cautious, with significant uncertainties surrounding its ability to raise additional capital and sustain operations in the near term.
About Mosaic ImmunoEngineering Inc.
Mosaic ImmunoEngineering is a biotechnology company focused on developing immunotherapies for cancer treatment. It aims to identify, license, and acquire innovative product candidates and platforms, leveraging expertise in immuno-oncology. The company explores novel therapies, including AI-driven combination strategies, with a pipeline primarily in early-stage preclinical development, targeting unmet medical needs in oncology markets worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.